Showing posts with label lofexidine for mitigating opioid withdrawal symptoms. Show all posts
Showing posts with label lofexidine for mitigating opioid withdrawal symptoms. Show all posts

Saturday, May 26, 2018

FDA Advisory Committee Votes in Favor of Lucemyra (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms

Lofexidine.svg



US WorldMeds,  announced that the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 11 to 1 to recommend approval of lofexidine for mitigating opioid withdrawal symptoms. If approved, lofexidine will be marketed under the brand name Lucemyra.

The Advisory Committee's discussions were based on US WorldMeds' New Drug Application (NDA) for Lucemyra, which is currently under priority review by the FDA. The NDA includes data from two randomized, double-blind, placebo-controlled clinical trials and several supporting studies that examined the safety and efficacy of Lucemyra.
Lucemyra suppresses the neurochemical surge that produces the acute and painful symptoms of opioid withdrawal. In clinical trials compared to placebo, participants treated with Lucemyra experienced less severe withdrawal symptoms and were more likely to complete a seven-day opioid discontinuation treatment. If approved, Lucemyra will be the first and only non-opioid medication indicated for the mitigation of opioid withdrawal symptoms. Opioid withdrawal symptoms may include feeling sick, stomach cramps, muscle spasms/twitching, feeling of coldness, heart pounding, muscular tension, aches/pains, yawning, runny eyes, insomnia/problems sleeping.
"Today's favorable recommendation brings us one step closer to providing evidence-based medication, and hope for recovery, to people who want to discontinue opioid use and are struggling with the agonizing symptoms of opioid withdrawal, one of the most powerful factors driving opioid dependence and addictive behaviors," said Mark Pirner, M.D., Ph.D., senior medical director. "We look forward to working closely with the FDA to bring this much-needed medication to people in the United States."
The FDA will consider the Advisory Committee's non-binding recommendation in its review of the NDA for Lucemyra. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in the second quarter of 2018.
https://en.wikipedia.org/wiki/Lofexidine